Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:announcedLiquidation |
2023
|
| gptkbp:CEO |
gptkb:Josh_Lehrer
|
| gptkbp:focusesOn |
gene editing
genetic medicines |
| gptkbp:foundedYear |
2017
|
| gptkbp:founder |
gptkb:Josh_Lehrer
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Graphite Bio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
GBT601
gene editing therapies for sickle cell disease |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:status |
ceased operations
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
GRPH
|
| gptkbp:website |
https://www.graphitebio.com/
|
| gptkbp:bfsParent |
gptkb:Versant_Ventures
|
| gptkbp:bfsLayer |
7
|